We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$5.41M
Cap. Flow %
-0.08%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.81%
2 Financials 1.53%
3 Miscellaneous 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$143B
$98.1M 1.4%
+720,679
New +$91.1M
BHC icon
27
Bausch Health
BHC
$2.21B
$95.2M 1.36%
3,183,100
-129,200
-4% -$3.36M
DCPH
28
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$94.2M 1.35%
1,514,171
-946,400
-38% -$45M
GKOS icon
29
Glaukos
GKOS
$10.1B
$84.3M 1.2%
+1,547,646
New +$94.2M
PTCT icon
30
PTC Therapeutics
PTCT
$5.55B
$83.1M 1.19%
1,729,200
-229,700
-12% -$9.76M
NTRA icon
31
Natera
NTRA
$47.4B
$82.2M 1.17%
2,440,613
-559,515
-19% -$20.6M
REGN icon
32
Regeneron Pharmaceuticals
REGN
$81.7B
$78.6M 1.12%
209,300
-18,800
-8% -$6.33M
ARVN icon
33
Arvinas
ARVN
$549M
$78M 1.11%
1,898,800
-196,483
-9% -$5.75M
QURE icon
34
uniQure
QURE
$3.12B
$77.5M 1.11%
1,081,765
+242,165
+29% +$13.3M
TMO icon
35
Thermo Fisher Scientific
TMO
$227B
$71.6M 1.02%
220,500
-131,400
-37% -$39.8M
MGTX icon
36
MeiraGTx Holdings
MGTX
$1.23B
$69.1M 0.99%
3,453,020
+103,960
+3% +$1.78M
TNDM icon
37
Tandem Diabetes Care
TNDM
$1.17B
$68M 0.97%
1,141,390
+477,000
+72% +$29.4M
EXEL icon
38
Exelixis
EXEL
$13.9B
$66.1M 0.94%
3,753,700
-159,200
-4% -$2.7M
ABT icon
39
Abbott
ABT
$178B
$62.1M 0.89%
715,100
-107,300
-13% -$8.99M
HZNP
40
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$57.3M 0.82%
+1,582,300
New +$48.5M
KRYS icon
41
Krystal Biotech
KRYS
$10.3B
$55.1M 0.79%
994,808
+392,858
+65% +$19.3M
BLU
42
DELISTED
BELLUS Health Inc.
BLU
$53.1M 0.76%
7,025,832
– –
DXCM icon
43
DexCom
DXCM
$31.3B
$51.4M 0.73%
939,600
-596,400
-39% -$28.3M
CRNX
44
DELISTED
Crinetics Pharmaceuticals
CRNX
$51.2M 0.73%
2,039,282
– –
ADVM
45
DELISTED
Adverum Biotechnologies
ADVM
$50M 0.71%
434,219
+32,922
+8% +$2.9M
AUPH icon
46
Aurinia Pharmaceuticals
AUPH
$2.14B
$47.5M 0.68%
2,345,447
-1,185,555
-34% -$10.9M
CRSP icon
47
CRISPR Therapeutics
CRSP
$5.12B
$46.7M 0.67%
766,378
+249,978
+48% +$13.6M
LOGC
48
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$46.6M 0.66%
6,466,783
– –
PRTA icon
49
Prothena Corp
PRTA
$458M
$45.9M 0.66%
2,902,239
-119,878
-4% -$1.29M
ATNX
50
DELISTED
Athenex, Inc. Common Stock
ATNX
$42.3M 0.6%
138,611
-26,835
-16% -$7.09M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.